Analyst: Bavarian drug could have a strong position, but…
Analyst Peter Aabo from Nordic Bio Investor has more faith in a type of prostate cancer vaccine being developed by US rival Dendreon, than he has for a drug from Bavarian. But the main challenge for the Americans – the high cost of manufacturing – could give the Danes an edge.
by Stefan Singh Kailay
Danish company Dandrit is developing a cancer vaccine, as is another Danish company, Bavarian Nordic. US company Dendreon’s own vaccine, Provenge, has disappointed, while Johnson & Johnson’s Zytiga is performing great.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
